



04-1107

IFW

Dkt. No. 29248/18

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant : Erik Buntinx
Appl. No. : 10/725,965
Filed : December 2, 2003
For : METHOD OF TREATING MENTAL DISORDERS USING
OF D4 AND 5-HT2A ANTAGONISTS, INVERSE AGONISTS
OR PARTIAL AGONISTS
Art Unit : 1617
Examiner : Umamaheswari Ramachandran
Customer No.: 1912

COMMUNICATION IN REPLY TO MARCH 13, 2007 OFFICE ACTION
AND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

"Express Mail" mailing label No. EV 725834781 US
Date of Deposit: April 10, 2007

I hereby certify that this paper or fee is being
deposited with the United States Postal Service
"Express Mail" service under 37 CFR 1.10 on the date
indicated above and is addressed to the
Commissioner for Patents, P.O. Box 1450, Alexandria,
VA 22313-1450.

Name: Alan D. Miller
Signature: 

Sir:

This Communication is submitted in response to the Office Action issued
on March 13, 2007 in connection with the above-identified application. A reply is due by
April 13, 2007. Accordingly, this Communication is being timely filed.

Applicant: Erik Buntinx
Appl'n. No.: 10/725,965
Filed: December 2, 2003
Page 2 of 3

REMARKS

Claims 32-77 are pending in the subject application.

In the March 13, 2007 Office Action, the Examiner requested that applicant make an election of claims to pursue in the application together with an election of species.

In response to the restriction requirement, applicant hereby elects Group II, Claims 41-42, drawn to a pharmaceutical composition comprising (a) a compound having (i) a selective affinity for the Dopamine-4 (D4) receptor and (ii) a selective affinity for the 5-HT2A receptor, and (b) a selective serotonin re-uptake inhibitor, as a combined preparation for simultaneous, separate or sequential use for treating a disease or disorder with an underlying dysregulation of emotional functionality.

With respect to the species election, applicant elects the following:

(i) for disease or disorder - mood disorders;
(ii) for a compound having a selective affinity for the Dopamine-4 (D4) receptor and the 5-HT2A receptor - pipamperone; and
(iii) for the selective serotonin re-uptake inhibitor - citalopram.

Claims 41-42 encompass the elected invention.

Supplemental Information Disclosure Statement

This Supplemental Information Disclosure Statement is being filed to supplement the Information Disclosure Statement filed on August 9, 2005 in connection with the above-identified application.

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicant would like to direct the Examiner's attention to the twenty references that are listed on enclosed Forms PTO/SB/08A-B (2 pages). Copies of the nine non-patent literature documents are attached hereto. Non-English language Reference numbers 12-14 on the enclosed Forms were cited in an Official Communication issued in patent family member

Applicant: Erik Buntinx
Appl'n. No.: 10/725,965
Filed: December 2, 2003
Page 3 of 3


European Patent Application EP 04 025 035.9; copies of relevant pages from the Official Communication are attached hereto (2 pages).

Applicant is submitting the subject Supplemental Information Disclosure Statement pursuant to 37 C.F.R. §1.97(b)(3) before the mailing of a first Office Action on the merits. Accordingly, no fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement.

No fee is deemed necessary in connection with the submission of this reply. However, if any fee is required in connection with this submission or to maintain the pendency of the subject application, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 01-1785.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN LLP
Attorneys for Applicant
90 Park Avenue
New York, New York 10016
(212) 636-8000

By 
Alan D. Miller, Reg. No. 42,889

Dated: April 10, 2007
New York, New York